

## Press Release

# Oversubscribed Financing Round for HEMEX

**HEMEX is delighted to announce the successful completion of an oversubscribed Series C to further accelerate the company's growth.**

- HEMEX welcomes a group of experienced Swiss entrepreneurs and private investors. The company is proud to be part of a strong network of like-minded people with ambitious goals.
- Significant capital contribution will enable HEMEX to strengthen its team, increase service offerings and accelerate the company's global expansion.
- HEMEX is committed to the continuous financial support of a select number of innovative and pioneering start-ups to bring state-of-the-art technologies to market.

---

**Liestal, February 10, 2021 – HEMEX, a bench-to-market Life Science consulting services and investment firm, announces the successful completion of an oversubscribed financing round. A substantial amount was raised exclusively from a group of Swiss private investors. HEMEX will use the funds to continue hiring world-class talent to boost and strengthen the company's growth, invest in carefully selected start-ups, and deliver on HEMEX's promise of changing the future of healthcare.**

HEMEX was founded in 2015 in Liestal, Basel Country, as a consulting company for Life Science start-ups. In 2017, HEMEX opened a subsidiary in Germany (Loerrach, BW) and in 2018 did the same in the USA (Bethesda, MD). In 2019, the company signed an exclusive partnership in China's Henan province and is now furthering its global expansion with additional locations in Orlando, FL, and Singapore.

Currently, HEMEX offers Life Science start-ups all services required to bring lead products to the market, especially throughout the Clinical Development phase (clinical trials, regulatory affairs, quality assurance). The HEMEX team has strong expertise and knowledge in innovative pharmaceuticals, medical devices, *in vitro* diagnostics, and digital health applications, both in human and animal health ("One Health").

Additionally, HEMEX supports start-ups financially through investments in early-stage financing rounds. The company also takes an active role in the due diligence and subsequent management of the company through board roles and executive leadership support.

HEMEX's offering is unique. It is specialized in accelerating high-tech Life Science research from the best universities by providing top-notch infrastructure such as office and lab space, years of development expertise, and access to a global network of dedicated early-stage co-investors. Our fast-growing team consists of highly trained healthcare development professionals and is complemented by a strong network of pre-qualified consultants, laboratories, CMOs, warehouses, logistic partners, and affiliates.

Pascal Winnen, CEO of HEMEX, commented: "We anticipate another year of strong growth for healthcare, both domestically and on a global level. We will continue to attract top talent from world-class universities, with great new employees joining the HEMEX team and through the support of innovative Life Science start-ups. This vote of confidence for our business model from a group of successful entrepreneurs confirms that HEMEX is on the right track for substantial future success."

For more information, please contact:

**Pascal Winnen, CEO**

[pascal.winnen@hemex.ch](mailto:pascal.winnen@hemex.ch)

+41 61 927 28 01

### **About HEMEX**



HEMEX is committed to changing the future of healthcare by guiding the most promising European start-ups through each and every step to bring innovative pharmaceuticals, medical devices and in vitro diagnostics to the market. Headquartered close to the thriving Basel global Life Sciences hub, the goal at HEMEX is to ensure start-ups have access to a wide range of tailored products, practical solutions, and fundraising support. This empowers the next generation of transformative discoveries to grow into successful and sustainable businesses and drive change in both human and animal healthcare. For more information, visit <https://hemex.ch/>